基于用药指导下的重组人干扰素α-2b喷雾剂治疗疱疹性咽峡炎的效果分析  

Efficacy of recombinant human interferonα-2b spray,administered under medication guidance,in the treatment of herpangina

作　　者：童敏青 林志刚 朱莉莉 徐顺芯 Tong Minqing;Lin Zhigang;Zhu Lili;Xu Shunxin(Pediatric Emergency Department,The First People's Hospital of Yongkang,Yongkang 321300,Zhejiang Province,China;Pediatric Inpatient Department,The First People's Hospital of Yongkang,Yongkang 321300,Zhejiang Province,China;Department of Pediatrics,Yongkang Maternity and Child Care Hospital,Yongkang 321300,Zhejiang Province,China)

机构地区：[1]永康市第一人民医院儿科门急诊,永康321300 [2]永康市第一人民医院儿科住院部,永康321300 [3]永康市妇幼保健院儿内科,永康321300

出　　处：《中国基层医药》2024年第4期505-509,共5页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨基于用药指导下的重组人干扰素α-2b喷雾剂应用于疱疹性咽峡炎治疗中的临床效果。方法选取2020年10月至2022年10月永康市第一人民医院收治的疱疹性咽峡炎患儿76例,采用随机数字表法将其分成观察组(n=42)和对照组(n=34),对照组给予常规治疗,观察组采用基于用药指导下的重组人干扰素α-2b喷雾剂治疗。比较两组治疗效果、炎性因子水平、治疗依从性及咽拭子病毒学转阴率。结果治疗后,观察组治疗总有效率[95.24%(40/42)]、治疗依从性[97.62%(41/42)]高于对照组[76.47%(26/34)、79.41%(27/34)](χ^(2)=4.27、4.82,P=0.040、0.030)。观察组C反应蛋白(CRP)[(6.28±1.64)mg/L]、白细胞计数[(6.11±1.10)×10^(9)]、血清淀粉样蛋白A[(3.47±0.89)mg/L],显著低于对照组[(7.51±1.16)mg/L、(7.51±1.16)×10^(9)、(7.82±1.30)mg/L](t=3.69、6.46、17.27,均P<0.001)。观察组咽拭子病毒学阳性率[4.76%(2/42)]低于对照组[26.47%(9/34)](χ^(2)=5.51,P=0.190)。结论基于用药指导下的重组人干扰素α-2b喷雾剂应用于疱疹性咽峡炎治疗中可提高治疗依从性,使得临床症状得以快速缓解,预后效果提升明显。Objective To investigate the efficacy of recombinant human interferonα-2b spray,administered under medication guidance,in the clinical treatment of herpangina.Methods A total of 76 children with herpangina who were treated at The First People's Hospital of Yongkang between October 2020 and October 2022 were included in this study.Using the random number table method,these patients were randomly assigned to an observation group(n=42)and a control group(n=34).The control group received conventional treatment,whereas the observation group was administered recombinant human interferonα-2b spray under medication guidance.A comparative analysis was conducted between the two groups,evaluating clinical efficacy,inflammatory factor levels,treatment compliance,and the negative conversion rate of throat swab virology.Results After treatment,the overall response rate of the observation group[95.24%(40/42)]and treatment compliance[97.62%(41/42)]were significantly higher than those of the control group[76.47%(26/34),79.41%(27/34),χ^(2)=4.27,4.82,P=0.040,0.030].The levels of C-reactive protein[(6.28±1.64)mg/L],white blood cell count[(6.11±1.10)×10^(9)],and serum amyloid A[(3.47±0.89)mg/L]in the observation group were significantly lower than those in the control group[(7.51±1.16)mg/L,(7.51±1.16)×10^(9),(7.82±1.30)mg/L,t=3.69,6.46,17.27,all P<0.001].The positive conversion rate of throat swab virology in the observation group[4.76%(2/42)]was lower than that in the control group[26.47%(9/34),χ^(2)=5.51,P=0.190].Conclusion The use of recombinant human interferonα-2b spray under medication guidance in the treatment of herpangina can improve treatment compliance,rapidly alleviate clinical symptoms,and significantly improve the prognosis.

关 键 词：疱疹性咽峡炎 炎症趋化因子类 预后 服药依从性 儿童 

分 类 号：R766.12[医药卫生—耳鼻咽喉科]